Drug intelligence / Profile preview

Xedra

Development stage: Unknown
Lead developer: Cipher Pharmaceuticals

Overview

Xedra is a branded dermatology product that was part of Innocutis Dermatology, Inc.'s portfolio of nine marketed products in the U.S. It was acquired by Cipher Pharmaceuticals Inc. in August 2015 as part of Cipher's strategy to expand its U.S. commercial presence and dermatology franchise. Specific details regarding its active ingredient, mechanism of action, and primary indication are not publicly available through general search.

Brand names: Xedra

Beyond the preview

Go deeper on Xedra.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xedra.

Explore the full profile